EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test

Zacks2024-11-18

Exact Sciences Corporation EXAS has unveiled data highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of the DETECT-A (Detecting cancers...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484738296?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","is_english":true,"pubTime":"2024-11-18 20:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484738296","market":"us","top_or_hot":-1,"title":"EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test","media":"Zacks","content":"<div>\n<p>Exact Sciences Corporation EXAS has unveiled data highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of the DETECT-A (Detecting cancers...</p>\n\n<a href=\"https://finance.yahoo.com/news/exas-stock-set-benefit-favorable-120700720.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 20:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/exas-stock-set-benefit-favorable-120700720.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Exact Sciences Corporation EXAS has unveiled data highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of the DETECT-A (Detecting cancers...</p>\n\n<a href=\"https://finance.yahoo.com/news/exas-stock-set-benefit-favorable-120700720.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEN","symbol_name":"Penumbra Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/exas-stock-set-benefit-favorable-120700720.html","article_id":"2484738296","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484738296","pubTimestamp":1731931620,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Exact Sciences CorporationEXAS has unveiled data highlighting significant advancements in the development of a multi-cancer early detection  test. The results of the DETECT-A  study, which evaluated a new multi-biomarker class approach, showed improved sensitivity for early-stage and overall cancer detection.The findings from the study were presented at the AACR  Special Conference: Liquid Biopsy 2024, held in San Diego, CA.After the Nov. 13 announcement, EXAS’ shares dipped 1.7%, finishing at $49.33 on Friday. On a positive note, the Exact Sciences team is advancing in its most impactful programs — colon cancer screening, molecular residual disease testing and multi-cancer screening. The company also has plans to introduce several novel tests, which will revolutionize how cancer is identified, tracked and managed, further fueling its growth. Accordingly, we expect the market sentiment surrounding the EXAS stock to remain positive surrounding this development.Exact Sciences currently h","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEN":"Penumbra Inc","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","EXAS":"精密科学","LU0266512127.USD":"摩根大通环球自然资源 A(acc)","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","HAE":"美国血液技术","BK4082":"医疗保健设备","LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4198":"医疗保健用品","BK4588":"碎股","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","MP":"MP Materials Corp.","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","GMED":"Globus Medical Inc","BK4548":"巴美列捷福持仓","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","CRC":"加州资源","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4213":"石油与天然气的勘探与生产","BK4168":"多种金属与采矿","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC"},"translate_title":"EXAS股票将受益于支持MCED测试的有利研究数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"HAE":1,"GMED":1,"EXAS":1,"CRC":1,"MP":1},"content_text":"Exact Sciences Corporation EXAS has unveiled data highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of the DETECT-A (Detecting cancers Early Through Elective mutation-based blood Collection and Testing) study, which evaluated a new multi-biomarker class approach, showed improved sensitivity for early-stage and overall cancer detection.\nThe findings from the study were presented at the AACR (American Association of Cancer Research) Special Conference: Liquid Biopsy 2024, held in San Diego, CA.\nLikely EXAS Stock Movement Following the News\nAfter the Nov. 13 announcement, EXAS’ shares dipped 1.7%, finishing at $49.33 on Friday. On a positive note, the Exact Sciences team is advancing in its most impactful programs — colon cancer screening, molecular residual disease testing and multi-cancer screening. The company also has plans to introduce several novel tests, which will revolutionize how cancer is identified, tracked and managed, further fueling its growth. Accordingly, we expect the market sentiment surrounding the EXAS stock to remain positive surrounding this development.\nExact Sciences currently has a market capitalization of $9.13 billion. The company has an estimated long-term earnings growth of 37.1% compared with the industry’s 21%. It has delivered an earnings beat of 29.94%, on average, in the trailing four quarters.\nRelevance of Exact Sciences’ New Study\nCancer is pacing to become the leading cause of death in the United States by 2030, yet only 14% of all cancers are currently diagnosed through screening. MCED testing is a major opportunity to address this stark gap in patient care.\nThe company’s DETECT-A study was the first-ever large, prospective, interventional study to use a blood test to detect multiple types of cancer in a real-world setting. It enrolled more than 10,000 women with no history of cancer to determine if a blood test in combination with standard-of-care screenings could detect cancers before signs and symptoms appeared.\nImage Source: Zacks Investment Research\nThe research will help inform the final design of Exact Sciences’ Cancerguard test, which is currently in development and intends to harness the additive sensitivity of multiple biomarker classes to detect more cancers in earlier stages.\nMore on EXAS’ Study Findings\nThe study demonstrates the ability of a multi-biomarker class MCED test to improve early-stage sensitivity by incorporating a DNA mutation reflex approach to methylation and protein (MP) test results. When excluding breast and prostate cancer and at a 98.5% specificity, sensitivity increased by 28% for stage I cancers and 12.5% for early-stage cancers (stages I and II) in a case-control study, underscoring the potential of a three-biomarker class (DNA methylation, protein, DNA mutation reflex, or MP-r) test to improve the detection of cancer in earlier stages.\nIn addition, new modeling data estimate that adding MCED testing to recommended screening may reduce the incidence of stage IV cancer and, subsequently, cancer mortality over 10 years. Another new analysis from the study suggests that adding MCED testing complements guideline-recommended lung cancer screening without affecting adherence to the current standard of care.\nIndustry Prospects Favoring EXAS\nPer a Grand View Research Report, the global MCED market is valued at $993 million (estimated) in 2023 and is likely to grow at a compound annual rate of 16.6% by 2030. The rising prevalence of multiple cancers and the demand for early detection methods are fueling the market growth.\nMore Updates From EXAS\nLast month, Exact Sciences secured FDA’s approval for its Cologuard Plus test, approved for adults ages 45 and above who are at average risk for colorectal cancer (CRC). The approval is based on the results from the pivotal BLUE-C study, one of the largest prospective, head-to-head studies ever conducted in CRC screening.\nEXAS Stock Price Performance\nIn the past six months, EXAS' shares have lost 3.3% compared with the industry’s decline of 6.2%.\nEXAS’ Zacks Rank and Key Picks\nExact Sciences currently carries a Zacks Rank #4 (Sell).\nSome better-ranked stocks in the broader medical space are Penumbra PEN, Haemonetics HAE and Globus Medical GMED, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nPenumbra’s shares have risen 1%% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.\nEstimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 7.6% in the past year compared with the industry’s growth of 21.5%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.\nEstimates for Globus Medical’s 2024 earnings per share have increased 0.4% to $2.95 in the past 30 days. Shares of the company have surged 81.1% in the past year compared to the industry’s 23.4% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nExact Sciences Corporation (EXAS) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484738296"}